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A new de novo protein design framework and its applications to the redesign of compstatin,
human beta defensin-2, and the C-terminal analogs of Complement 3a is presented.
1 Introduction
De novo protein design searches for amino acid sequences that are compatible with a
three-dimensional protein backbone template. Traditionally the backbone coordinates were
treated as fixed in order to reduce the search space and make the design problem tractable.
However, this is a highly questionable assumption as proteins are known to exhibit back-
bone flexibility. In de novo design, backbone flexibility was incorporated through either
the consideration of multiple backbones with sequence search performed on each of them
under the fixed template assumption, or the parameterization of backbone16. Recently
we have developed a novel framework which performs de novo design on a truly flexible
backbone template, which is defined by continuous Cα-Cα distances and dihedral angles
between upper and lower bounds, through NMR structure refinement.
2 Our De Novo Protein Design Framework
Our two-stage de novo protein design framework not only selects and ranks amino acid
sequences for a particular fold using a novel integer linear programming (ILP) model, but
also validates the specificity to the fold for these sequences based on the full-atomistic
forcefield AMBER1. The two stages are outlined as below:
2.1 Stage One: In Silico Sequence Selection
The ILP model we use for sequence selection into a single template structure, which is the
most computationally efficient one among 13 equivalent formulations we studied9, takes
the form:
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Set i = 1, . . . , n defines the number of residue positions along the template. At each
position i there can be a set of mutations represented by j{i} = 1, . . . ,mi, where for the
general case mi = 20∀i. The equivalent sets k ≡ i and l ≡ j are defined, and k > i
is required to represent all unique pairwise interactions. Binary variables yji and ylk are
introduced to indicate the possible mutations at a given position. Specifically, variable
yji (y
l
k) will be one if position i(k) is occupied by amino acid j(l), and zero otherwise.
The composition constraints require that there is exactly one type of amino acid at each
position. The pairwise energy interaction parameters Ejlik were empirically derived by
solving a linear programming parameter estimation problem, which restricts the low energy
high resolution decoys for a large training set of proteins to be ranked energetically less
favorable than their native conformations2.
Besides the basic model (1), we also developed a weighted average model and a binary
distance bin model10 for de novo design based on a flexible template with multiple crystal
or solution structures.
2.2 Stage Two: Approximate Method for Fold Validation
Driven by the full atomistic forcefield AMBER1, simulated annealing calculations are per-
formed for an ensemble of several hundred random structures generated for each sequence
from stage one using CYANA 2.13, 4 within the upper and lower bounds on Cα-Cα dis-
tances and dihedral angles input by the user. This feature allows our framework to observe
true backbone flexibility5. The TINKER package6 is subsequently used for local energy
minimization of these conformers. A fold specificity factor is finally computed for each
sequence using the following equation:
fspecificity =
P
i∈new sequence conformers exp[−βEi]P
i∈native sequence conformers exp[−βEi] (2)
3 Case Studies
3.1 Compstatin
Compstatin (PDB code: 1A1P) is a synthetic 13-residue cyclic peptide that inhibits the
cleavage of C3 to C3a and C3b in the human complement system and thus hinders com-
plement activation. It is a novel drug candidate for treating inappropriate complement ac-
tivation that has shown highly promising results in numerous pre-clinical trials conducted
recently. The de novo design on compstatin is aimed at acquiring the sequences for the best
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Figure 1. Flexible template of compstatin for de novo protein design as illustrated by the overlapping of its 21
NMR structures available from the Protein Data Bank.
inhibitors to C3. It was performed based on the flexible template of all 21 NMR structures
available from the Protein Data Bank (Fig. 1).
As for the mutation set of the design, Cys2 and Cys12 were kept invariant to main-
tain the disulfide bridge in order to aid the formation of the hydrophobic cluster and pro-
hibit the termini from drifting apart. The type I β-turn, Gln5-Asp6-Trp7-Gly8, was also
fixed as it was not found to be a sufficient condition for activity. Val3 and Trp7 were not
mutated either as they were found to interact directly with C3. For the varied positions,
positions 1, 4 and 13 were allowed to select only from the hydrophobic amino acid set
(A,F,I,L,M,W,V,Y). In addition, this set included threonine for position 13 to allow for the
selection of the wild type residue at this position. For positions 9, 10, and 11, all residues
were allowed, excluding cysteine and tryptophan. This mutation set leads to a problem
with complexity 3.0× 106. Results for the design can be found in10.
3.2 Human Beta Defensin-2
Human Beta Defensin-2 (hβD-2) is a cysteine-rich 41-residue cationic peptide found in
the human immune system. It belongs to the class of small, cationic peptides known as
defensins. hβD-2 is crucial to innate immunity11. It possesses antimicrobial property
derived from the electrostatic force between the positive charge on the defensin molecule
and the negative charge of the anionic head group of the microbe’s membrane lipids. This
electrostatic force disrupts the microbe’s cell membrane and thus kills the cell11.
Three different sets of flexible design templates were employed for the de novo design
of hβD-2. The first one corresponds to the X-ray crystal structure elucidated by11(PDB
code: 1FD3) at a resolution of 1.35A˚. The other two were generated using molecular
dynamics simulation with generalized Born implicit solvation (Fig. 2) and molecular dy-
namics simulation with explicit water molecules (not shown).
In the design of hβD-2, SASA patterning was applied to restrict the sequence search
space for the de novo design of hβD-2. The 41 positions of hβD-2 are classified into
the core, surface, and intermediate categories which determine the mutation set for each
position. This corresponds to the full-squence design of the antimicrobial peptide with
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Figure 2. Overlay of the 10 structures of human beta-defensin-2 used for the flexible design template from MD
simulations with the GB implicit solvation model. The structures are snapshots with 1 ns increment.
problem complexity of 6.40× 1037.
It should be noted that in the sequence selection stage, biological constraints, which
were obtained from a homology search using PSI-BLAST, were imposed to ensure certain
conserved properties among the sequence solutions. The constraints added cover charge
characteristics, hydrophobic content, and amino acid occurrence frequencies of the human
beta defensin-2 homologs. Results for the de novo design can be found in12.
3.3 Complement 3a
Complement 3a (C3a) is a 77-residue small cationic peptide derived from the cleavage of
the amino-terminus of the α-chain of complement component C3. It is a potent mediator
which controls the pro-inflammatory activities of the complement system13. Having small
molecular size and high potency, C3a proves to be a strong candidate as a superior ther-
apeutic agent. Our de novo design aims at obtaining a potential peptide-drug candidate
based on the C-terminal sequence of the C3a fragment of C3.
Like the design of human beta defensin-2, three different sets of flexible templates were
employed. One corresponds to the single crystal structure elucidated by14, and the other
two were generated using molecular dynamics simulations, one with the generalized Born
implicit solvation model and the other with explicit water molecules (Fig. 3). The basic
sequence selection model (1) was used for the single crystal structure template, whereas
both the weighted average formulation and the binary distance bin formulation10 were
employed for the flexible templates from molecular dynamics simulation.
Table 1 shows the mutation set of the de novo design.
Results of the de novo design are tabulated in15. Several 15-residue peptides were se-
lected to be synthesized based on our predictions from the de novo design framework. The
best sequence was experimentally validated to be close in performance to the superpotent
peptide synthesized by13 in Ca2+ mobilization assay.
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Figure 3. Overlay of the 10 structures of Complement 3a used for the flexible design template from MD simula-
tions with the GB implicit solvation model.
Table 1. Mutation set of in silico sequence selection of C3a.
Positions Native residue Allowed mutations
63 L A,I,L,M,F,Y,W,V
64 R all except C and P
65 R R,N,D,Q,E,G,H,K,S,T
66 Q R,N,D,Q,E,G,H,K,S,T
67 H R,N,D,Q,E,G,H,K,S,T
68 A all except C and P
70 A R,N,D,Q,E,G,H,K,S,T
71 S R,N,D,Q,E,G,H,K,S,T
72 H R,N,D,Q,E,G,H,K,S,T
4 Conclusions
In this paper, we presented the advances in our de novo protein design models, as well as
our predictions on compstatin, human beta defensin-2, and C3a.
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